NIH DRUG DEVELOPMENT CONSULTING SERVICES

美国国立卫生研究院药物开发咨询服务

• 批准号: 8429009
• 负责人: PAUL PEARSON
• 金额: $ 5.8万
• 依托单位: PEARSON PHARMA PARTNERS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-20 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8429009
• 关键词: Address; Biological Assay; Biology; Consult; Contracts; Development; Development Plans; Disease; Funding; Future; Industry; Institutes; Lead; Leadership; Modeling; Neurosciences; Neurosciences Research; Peer Review; Pharmaceutical Preparations; Principal Investigator; Process; Research; Research Contracts; Research Personnel; Seasons; Services; Shapes; Therapeutic; United States National Institutes of Health; Work; design; drug development; experience; indexing; innovation; meetings; nervous system disorder; programs; virtual

In 2010, the NIH Blueprint for Neuroscience Research, representing sixteen NIH Institutes and Centers, announced a Grand Challenge for Neurotherapeutics to address the paucity of effective drugs for disorders of the nervous system. To meet this Grand Challenge, the NIH Blueprint is pioneering a new model for drug development¿a network that integrates industry drug development expertise with the innovative disease biology that is the strength of NIH-funded research. The Blueprint Neurotherapeutics Network will operate as a ¿virtual pharma¿ (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). Neuroscience researchers (principal investigators) with a compelling therapeutic rationale and starting materials for a drug development project will be matched with senior-level, industry-seasoned consultants who will design and direct the drug development plan. The principal investigators will conduct the bioactivity assays and biological work, and Contracted Research Organizations (CROs), which will be identified and funded by NIH through separate contracts, will implement all other drug development activities. The principal investigator, consultants, NIH staff, and CRO staff engaged in a project will constitute a Lead Development Team (LDT).

2010年，神经科学的NIH蓝图代表了16个NIH机构和中心CS，以解决有效的药物来应对这一巨大的挑战。一个将药物药物药物药物药物药物药物药物药物开发专业知识与Tilogy的网络与NIH资助的研究的强度。虚拟制药（http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm）调查人员将进行生物活性测定和生物学工作。开发团队（LDT）。